Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that Charles J. Casamento has been appointed chairman of the company's board of directors. Mr. Casamento has been a member of the Relmada Therapeutics board of directors since July 2015 and is also chairman of the audit committee and a member of the compensation and the corporate governance committees.
Since 2007, Mr. Casamento has been executive director and principal of The Sage Group, a health care advisory group. Previously he was president and CEO of Osteologix and founder, chairman and CEO of Questcor Pharmaceuticals. In 2015 Questcor was acquired by Mallinckrodt for approximately $6 billion. He also served as president, CEO and chairman of RiboGene Inc. and was co-founder, president and CEO of Indevus (formerly Interneuron Pharmaceuticals). In 2006 Indevus was acquired by Endo Pharmaceuticals for approximately $650 million. He has also held senior management positions at Genzyme Corporation, American Hospital Supply, Johnson & Johnson, Hoffmann-LaRoche and Sandoz. He has served as a director of eleven other pharmaceutical/biotechnology companies and has been on the board of two not for profit organizations.
"Charles Casamento has been an outstanding member of the Relmada board of directors, and in his new role as chairman his insights and expertise will play an even more important role in guiding and advancing our business strategy in the years ahead," said Sergio Traversa, chief executive officer of Relmada.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. The Company has a diversified portfolio of four products at various stages of development, including d-Methadone (dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist for depression and neuropathic pain; LevoCap ER (REL-1015), an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; oral buprenorphine (BuTab, REL-1028), an oral dosage form of the opioid analgesic buprenorphine; and topical mepivacaine (MepiGel, REL-1021), an orphan drug designated topical formulation of the local anesthetic mepivacaine. For more information, please visit Relmada's website at: www.relmada.com.
